| Literature DB >> 24895565 |
Ivanildo Mangueira da Silva1, João da Silva Filho2, Priscila Brandão Gomes da Silva Santiago1, Micalyne Soares do Egito1, Carlos André de Souza2, Frederico Leite Gouveia1, Rafael Matos Ximenes2, Kêsia Xisto da Fonseca Ribeiro de Sena2, Antonio Rodolfo de Faria1, Dalci José Brondani1, Julianna Ferreira Cavalcanti de Albuquerque3.
Abstract
Antibiotic resistance is considered one of the world's major public health concerns. The main cause of bacterial resistance is the improper and repeated use of antibiotics. To alleviate this problem, new chemical substances against microorganisms are being synthesized and tested. Thiazolidines are compounds having many pharmacological activities including antimicrobial activities. For this purpose someEntities:
Mesh:
Substances:
Year: 2014 PMID: 24895565 PMCID: PMC4033545 DOI: 10.1155/2014/316082
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Scheme 1Substituent in the synthesis of 5-arylidene-thiazolidine-2,4-dione (2a–i).
Antimicrobial activity of compounds tested against different microorganisms (diameter of inhibition halo in mm).
| Microorganisms | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Synthetized compounds | Gram-positive bacteria | Gram-negative bacteria | Alcohol acid resistant bacteria | Yeast | ||||||
|
| Subs. |
|
|
|
|
|
|
|
|
|
|
| — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
| 3-OCH3
| 19.3 ± 0.47 | 27.8 ± 0.16 | 11.2 ± 0.62 | 15.0 ± 0.16 | 15.0 ± 0.16 | 0 | 0 | 19.3 ± 0.77 | 16.2 ± 0.82 |
|
| 2,4-Cl | 11.7 ± 0.56 | 32.0 ± 0.81 | 18.8 ± 0.85 | 30.7 ± 0.47 | 0 | 0 | 0 | 19.2 ± 0.41 | 0 |
|
| 3,4-Cl | 19.4 ± 0.08 | 34.0 ± 0.80 | 8.4 ± 0.17 | 25.4 ± 0.05 | 0 | 0 | 0 | 12.1 ± 0.09 | 0 |
|
| 4-OH | 0 | 13.8 ± 0.56 | 11.0 ± 0.82 | 0 | 0 | 0 | 0 | 0 | 0 |
|
| 3-OCH3 | 0 | 12.7 ± 0.56 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
| 3-CH3 | 18.3 ± 0.47 | 0 | 18.8 ± 0.16 | 17.8 ± 0.62 | 0 | 0 | 0 | 0 | 0 |
|
| 3-NO2 | 21.8 ± 0.16 | 0 | 22.8 ± 0.70 | 23.7 ± 0.16 | 0 | 0 | 0 | 0 | 0 |
|
| 4-NO2 | 23.8 ± 0.16 | 0 | 21.9 ± 0.17 | 18.6 ± 0.15 | 0 | 0 | 0 | 0 | |
|
| 3-Cl | 20.8 ± 0.27 | 24.8 ± 0.16 | 21.8 ± 0.16 | 27.7 ± 0.16 | 0 | 0 | 0 | 0 | 0 |
|
| ||||||||||
| Kan | 23.0 ± 0.82 | 28.3 ± 0.09 | 0 | 14.0 ± 0.82 | 20.0 ± 0.12 | 15.1 ± 0.19 | 15.0 ± 0.12 | 40.0 ± 0.12 | — | |
| Cef | 35.3 ± 0.09 | 54.0 ± 0.12 | 24.1 ± 0.19 | 45.0 ± 0.12 | 0 | 24.3 ± 0.09 | 0 | 0 | — | |
| Ket | — | — | — | — | — | — | — | — | 24.1 ± 0.19 | |
Standard compounds: Cef: cephalexin; Ket: ketoconazole; Kan: kanamycin.
—: not tested; X: medium; δ: standard deviation.
Inhibition and bactericidal concentrations of compounds (2a–i), with respect to different microorganisms (μg/mL).
| Synthetized compounds | Microorganisms | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |||||||
| MIC | MBC | MIC | MBC | MIC | MBC | MIC | MBC | MIC | MBC | MIC | MBC | |
|
| 16 | 32 | 4 | 8 | 4 | 8 | 16 | 32 | 64 | >128 | 8 | 32 |
|
| 8 | 16 | 2 | 4 | 2 | 4 | 2 | 4 | 16 | 32 | — | — |
|
| 8 | 16 | 2 | 4 | 2 | 4 | 2 | 4 | 16 | 32 | — | — |
|
| — | — | 4 | 8 | — | — | — | — | — | — | — | — |
|
| — | — | 4 | 8 | — | — | — | — | — | — | — | — |
|
| 16 | 32 | 16 | 32 | 4 | 8 | — | — | — | — | — | — |
|
| 8 | 16 | 8 | 16 | 16 | 32 | — | — | — | — | — | |
|
| 8 | 16 | 8 | 16 | — | — | — | — | — | — | — | — |
|
| 8 | 16 | 16 | 32 | 4 | 8 | — | — | — | — | — | — |
|
| ||||||||||||
| Cefalexin | 8 | 16 | <2 | 2 | <2 | <2 | >128 | >128 | >128 | >128 | — | — |
| Ketoconazole | — | — | — | — | — | — | — | — | — | — | <2 | 2 |
MIC: minimum inhibitory concentration;
MBC: minimum bactericidal concentration;
—: not tested.